Impact of Early Tumour Shrinkage on Long-term Outcome In Metastatic Colorectal Cancer (mCRC) Treated With 5FU+Irinotecan plus Leucovorin (FOLFIRI) or Capecitabine plus Irinotecan XELIRI Plus Bevacizumab

被引：3
|
作者：
Ichante, J. L. [1 ]
Adenis, A. [2 ]
Francois, E. [3 ]
Boucher, E. [4 ]
Pignon, J. P. [1 ]
Ychou, M. [5 ]
Pierga, J. Y. [6 ]
Montotot-Grillo, C. [7 ]
Conroy, T. [8 ]
Ducreux, M. [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ctr Oscar Lambret, F-59020 Lille, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Ctr Val Aurelle, Montpellier, France
[6] Inst Curie, Paris, France
[7] Federat Ctr Lutte Canc, Paris, France
[8] Ctr Alexis Vautrin, Nancy, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71739-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [41] Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC).
    Baran, R
    McKenna, E
    Patt, Y
    Ghali, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 309S - 309S
  • [42] ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [44] Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer
    Choti, MA
    CANCER TREATMENT REVIEWS, 2004, 30 (08) : 715 - 720
  • [45] Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC
    Sobrero, Alberto
    Ackland, Stephen
    Carrion, Ramon Perez
    Chiarra, Silvana
    Clarke, Stephen
    Giron, Carlos Garcia
    Langer, Bernd
    Andre, Niko
    Young, Scott
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [46] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [47] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [48] Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab
    Al-Shamsi, Humaid O.
    Al Farsi, Abdulaziz
    Anjum, Mahraz
    Shen, Hua
    Zbuk, Kevin
    Cook, Richard J.
    Linkins, Lori-Ann
    Major, Pierre
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (03) : 274 - 279
  • [49] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
    Ducreux, M.
    Adenis, A.
    Pignon, J. -P.
    Francois, E.
    Chauffert, B.
    Ichante, J. L.
    Boucher, E.
    Ychou, M.
    Pierga, J. -Y.
    Montoto-Grillot, C.
    Conroy, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1236 - 1245
12345